During the late summer and early autumn of 2006, the medical community began to express second thoughts about the safety of drug-coated cardiac stents, which have in recent years been given credit for reducing the frequency of complications arising from the use of a previous generation of stents.
The publicity generated by the news media interested me in my professional role representing health care providers, and for personal reasons as well. In June 1999, I underwent coronary angioplasty and stent placement to address a 95 percent blockage of one coronary artery. I have been closely monitored in semi-annual visits since that time, and I recently discussed with my cardiologist the evolving technology of drug-coated stents. Our discussion led me to research the procedure in general, and the recent evolution of cardiac stents in use within the United States and abroad.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
